213 related articles for article (PubMed ID: 17603822)
1. Medical therapy for diabetes is associated with increased use of lower endoscopy.
Lewis JD; Capra AM; Achacoso NS; Ferrara A; Levin TR; Quesenberry CP; Habel LA
Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1195-202. PubMed ID: 17603822
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
Masoudi FA; Inzucchi SE; Wang Y; Havranek EP; Foody JM; Krumholz HM
Circulation; 2005 Feb; 111(5):583-90. PubMed ID: 15699279
[TBL] [Abstract][Full Text] [Related]
3. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
4. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones and fractures in men and women.
Dormuth CR; Carney G; Carleton B; Bassett K; Wright JM
Arch Intern Med; 2009 Aug; 169(15):1395-402. PubMed ID: 19667303
[TBL] [Abstract][Full Text] [Related]
6. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
[TBL] [Abstract][Full Text] [Related]
7. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
[TBL] [Abstract][Full Text] [Related]
8. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
Aquilante CL; Zhang W; McCollum M
Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
[TBL] [Abstract][Full Text] [Related]
9. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
Simpson SH; Majumdar SR; Tsuyuki RT; Eurich DT; Johnson JA
CMAJ; 2006 Jan; 174(2):169-74. PubMed ID: 16415461
[TBL] [Abstract][Full Text] [Related]
10. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
Walker AM; Koro CE; Landon J
Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):760-8. PubMed ID: 18383443
[TBL] [Abstract][Full Text] [Related]
11. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
[TBL] [Abstract][Full Text] [Related]
12. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
Gulliford M; Latinovic R
Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
[TBL] [Abstract][Full Text] [Related]
13. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.
Bo S; Ciccone G; Rosato R; Villois P; Appendino G; Ghigo E; Grassi G
Diabetes Obes Metab; 2012 Jan; 14(1):23-9. PubMed ID: 21812892
[TBL] [Abstract][Full Text] [Related]
14. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H
J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611
[TBL] [Abstract][Full Text] [Related]
15. A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006.
Casscells SW; Granger E; Swedorske J; Goldhammer R; Shaheen M; Dorris J; Hong A; Wiktor M
Am J Ther; 2008; 15(3):198-205. PubMed ID: 18496256
[TBL] [Abstract][Full Text] [Related]
16. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
Bowker SL; Lin M; Eurich DT; Johnson JA
Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
[TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
18. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
Sillars B; Davis WA; Hirsch IB; Davis TM
Diabetes Obes Metab; 2010 Sep; 12(9):757-65. PubMed ID: 20649627
[TBL] [Abstract][Full Text] [Related]
19. Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus.
Ravipati G; Aronow WS; Ahn C; Sujata K; Saulle LN; Channamsetty V; Weiss MB
Am J Ther; 2006; 13(5):400-3. PubMed ID: 16988534
[TBL] [Abstract][Full Text] [Related]
20. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
